CellCentric Makes Two Appointments
This article was originally published in Scrip
CellCentric, a company developing anti-cancer compounds, has appointed Nigel Brooks director of translational science and Martin Page consultant. Brooks was previously involved in AstraZeneca Plc's clinical trials and he also led the AstraZeneca urology disease area team. He currently holds a senior leadership role at the Manchester Cancer Research Centre. Page brings experience in oncology R&D and held various senior management positions including European oncology therapeutic area head for Glaxo-Wellcome, and global head of oncology research for Johnson & Johnson Pharmaceuticals where he was vice president.